Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma

NCT00794950 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
43
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Michigan